Ivan Lolli

1.1k total citations · 1 hit paper
40 papers, 672 citations indexed

About

Ivan Lolli is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ivan Lolli has authored 40 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Genetics and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ivan Lolli's work include Glioma Diagnosis and Treatment (16 papers), Brain Metastases and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ivan Lolli is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Brain Metastases and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ivan Lolli collaborates with scholars based in Italy and United States. Ivan Lolli's co-authors include Roberta Rudà, Francesco Pasqualetti, Riccardo Soffietti, Giuseppe Lombardi, Vittorina Zagonel, Gian Luca De Salvo, Marica Eoli, Simona Rizzato, Stefano Indraccolo and Alba A. Brandes and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Lancet Oncology.

In The Last Decade

Ivan Lolli

37 papers receiving 664 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

2018 257 citations Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ivan Lolli Italy	13	388	202	197	190	158	40	672
Marina Faedi Italy	13	412 1.1×	164 0.8×	213 1.1×	199 1.0×	157 1.0×	27	710
Mario Caccese Italy	17	450 1.2×	211 1.0×	224 1.1×	242 1.3×	253 1.6×	70	883
Katharina Seystahl Switzerland	16	434 1.1×	147 0.7×	196 1.0×	192 1.0×	230 1.5×	40	867
Richard Zuniga United States	6	360 0.9×	141 0.7×	211 1.1×	89 0.5×	121 0.8×	16	498
Scott Peak United States	7	438 1.1×	135 0.7×	281 1.4×	209 1.1×	131 0.8×	9	640
Gaspar Reynés Spain	14	472 1.2×	232 1.1×	219 1.1×	222 1.2×	371 2.3×	40	898
Emese Filka United States	6	533 1.4×	197 1.0×	202 1.0×	128 0.7×	240 1.5×	9	672
T. Mikkelsen United States	11	515 1.3×	205 1.0×	220 1.1×	134 0.7×	270 1.7×	21	731
Yong Cui China	17	367 0.9×	169 0.8×	272 1.4×	196 1.0×	168 1.1×	59	831
Debra C. LaFrankie United States	10	537 1.4×	180 0.9×	201 1.0×	120 0.6×	200 1.3×	19	701

Countries citing papers authored by Ivan Lolli

Since Specialization

Citations

This map shows the geographic impact of Ivan Lolli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Lolli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Lolli more than expected).

Fields of papers citing papers by Ivan Lolli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Lolli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Lolli. The network helps show where Ivan Lolli may publish in the future.

Co-authorship network of co-authors of Ivan Lolli

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Lolli. A scholar is included among the top collaborators of Ivan Lolli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Lolli. Ivan Lolli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donghia, Rossella, Alessandro Rizzo, Laura Troiani, et al.. (2023). Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers. 15(8). 2376–2376. 8 indexed citations

Lolli, Ivan, Anna Maria Valentini, Angela Dalia Ricci, & Raffaele Armentano. (2023). Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature. Journal of the National Comprehensive Cancer Network. 21(5). 442–448.e2. 2 indexed citations

Disciglio, Vittoria, Paola Sanese, Candida Fasano, et al.. (2022). Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors. Genes. 13(4). 644–644. 3 indexed citations

D’Alessandro, Rosalba, Maria Grazia Refolo, Rossella Donghia, et al.. (2022). Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study. Frontiers in Oncology. 12. 862116–862116. 4 indexed citations

Lombardi, Giuseppe, Paola Del Bianco, Alba A. Brandes, et al.. (2021). Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). European Journal of Cancer. 155. 179–190. 16 indexed citations

Indraccolo, Stefano, Gian Luca De Salvo, Mario Caccese, et al.. (2020). Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research. 26(17). 4478–4484. 28 indexed citations

Bongiovanni, Alberto, Chiara Liverani, Sara Pusceddu, et al.. (2020). Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. BMJ Open. 10(7). e034393–e034393. 16 indexed citations

Cavalcanti, Elisabetta, Raffaele Armentano, & Ivan Lolli. (2020). Crohn’s Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review. Cancer Research and Treatment. 52(4). 1291–1295. 12 indexed citations

Carbonara, Roberta, et al.. (2020). Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules. BMC Cancer. 20(1). 311–311.

10.

Refolo, Maria Grazia, Claudio Lotesoriere, Ivan Lolli, Caterina Messa, & Rosalba D’Alessandro. (2020). Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines. Scientific Reports. 10(1). 7162–7162. 21 indexed citations

11.

Disciglio, Vittoria, Candida Fasano, Filomena Cariola, et al.. (2019). Gastric polyposis and desmoid tumours as a new familial adenomatous polyposis clinical variant associated with APC mutation at the extreme 3′-end. Journal of Medical Genetics. 57(5). 356–360. 12 indexed citations

12.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2018). Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 20(1). 110–119. 257 indexed citations breakdown →

13.

Rosati, Gerardo, Carmine Pinto, Francesca Di Fabio, et al.. (2018). Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study. Journal of Geriatric Oncology. 9(3). 243–248. 5 indexed citations

14.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2017). REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients. Annals of Oncology. 28. v610–v610. 3 indexed citations

15.

Divella, Rosa, Antonella Daniele, Ines Abbate, et al.. (2014). The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer. Cancer Causes & Control. 25(11). 1531–1541. 27 indexed citations

16.

Santoni, Matteo, Silvia Scoccianti, Ivan Lolli, et al.. (2013). Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of Neuro-Oncology. 113(3). 397–401. 14 indexed citations

17.

Lolli, Ivan, Maria Grazia Fabrini, Giovanni Silvano, et al.. (2012). A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. Journal of Translational Medicine. 10(1). 90–90. 10 indexed citations

18.

Soffietti, Riccardo, Elisa Trevisan, Roberta Rudà, et al.. (2011). Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology).. Journal of Clinical Oncology. 29(15_suppl). 2027–2027. 11 indexed citations

19.

Fabrini, Maria Grazia, et al.. (2008). A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Journal of Neuro-Oncology. 92(1). 79–86. 47 indexed citations

20.

Sanguedolce, Francesca, et al.. (2005). Abdominal lymphangioleiomyomatosis in a man with Klinefelter syndrome: the first reported case. Annals of Diagnostic Pathology. 9(2). 96–100. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact